|
Title
|
|
|
|
A randomized phase II study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205)
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Radical multimodality treatment for malignant pleural mesothelioma (MPM) is controversial, with intense debate (but lack of data) about which surgical procedure to perform [extrapleural pneumonectomy (EPP) or pleurectomy/decortication (PD)], if any. In order to perform a randomized comparison, the most optimal sequence of surgery and chemotherapy should be determined. EORTC 1205 is a clinical trial randomizing between upfront surgery, followed by chemotherapy (cisplatin plus pemetrexed) and deferred surgery, following neoadjuvant chemotherapy in early stage (T1-3 N0-2 M0) MPM (irrespective of histological subtype). The surgical procedure performed is (extended) pleurectomy/decortication (e-PD), which is promoted as an alternative for EPP, but lacks standardization. Primary outcome parameter is successful completion of multimodality treatment; secondary outcome parameters are surgical quality parameters (in order to standardize the procedure), progression free survival (PFS) and overall survival (OS), treatment-failure free survival, operative morbidity and mortality, toxicity and safety. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Translational lung cancer research. - -
| |
|
Publication
|
|
|
|
Shatin
:
Ame publ co
,
2018
| |
|
ISSN
|
|
|
|
2218-6751
| |
|
Volume/pages
|
|
|
|
7
:5
(2018)
, p. 593-598
| |
|
ISI
|
|
|
|
000447690700012
| |
|
Pubmed ID
|
|
|
|
30450298
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (publisher's version - intranet only)
|
|
|
|
| |
|